National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

recombinant vaccinia-CEA(6D)-TRICOM vaccine
A vaccine consisting of recombinant vaccinia virus encoding the tumor-associated antigen carcinoembryonic antigen (CEA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1, and LFA-3; also called TRICOM). Vaccination with recombinant vaccinia-CEA(6D)-TRICOM vaccine stimulates the host immune system to mount a T-cell response against tumor cells expressing the CEA antigen. The use of TRICOM in the vaccine may elicit a greater antitumor cytotoxic T lymphocyte (CTL) immune response compared to the use of vaccinia-CEA alone. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:rV-CEA(6D)-TRICOM



Previous:recombinant transforming growth factor-beta-2, recombinant tumor necrosis factor family protein, recombinant tyrosinase-related protein-2, recombinant vaccinia prostate-specific antigen vaccine, recombinant vaccinia-B7.1 vaccine
Next:recombinant vaccinia-MUC-1 vaccine, recombinant vaccinia-multiepitope melanoma peptides-B7.1-B7.2 vaccine, recombinant vaccinia-NY-ESO-1 vaccine, recombinant vaccinia-TRICOM vaccine, Rectoid

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov